Literature DB >> 35698683

Use of Azathioprine in Ulcerative Colitis: A Comprehensive Review.

Bipadabhanjan Mallick1, Sarthak Malik2.   

Abstract

Ulcerative colitis (UC) is a relapsing and remitting chronic inflammatory disease of the large intestine characterized by bloody diarrhea, abdominal pain, urgency, and tenesmus. Rapid induction and maintenance of remission are the primary goals of treatment. Azathioprine (AZA), a purine analog, has been utilized as an immuno-modulator to maintain remission in UC. AZA has been used for a long time, but there is still controversy about its effectiveness, drug interactions, and side effects in people with UC. We conducted a comprehensive analysis of the literature and present a detailed insight into the role of AZA in patients with UC.
Copyright © 2022, Mallick et al.

Entities:  

Keywords:  adverse drug reaction; azathioprine; efficacy; inflammatory bowel disease; ulcerative colitis

Year:  2022        PMID： 35698683      PMCID： PMC9184176          DOI： 10.7759/cureus.24874

Source DB:  PubMed          Journal:  Cureus        ISSN： 2168-8184


  89 in total

1.  Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial.

Authors:  A Sood; V Midha; N Sood; V Kaushal
Journal:  Indian J Gastroenterol       Date:  2000 Jan-Mar

2.  Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Authors:  Harry Sokol; Laurent Beaugerie; Marc Maynadié; David Laharie; Jean-Louis Dupas; Bernard Flourié; Eric Lerebours; Laurent Peyrin-Biroulet; Matthieu Allez; Tabassome Simon; Fabrice Carrat; Nicole Brousse
Journal:  Inflamm Bowel Dis       Date:  2012-01-23       Impact factor: 5.325

3.  Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine.

Authors:  B Bonaz; J Boitard; P Marteau; M Lémann; B Coffin; B Flourié; J Belaiche; G Cadiot; E-H Metman; A Cortot; J-F Colombel
Journal:  Aliment Pharmacol Ther       Date:  2003-08-15       Impact factor: 8.171

4.  Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy.

Authors:  S Campbell; S Ghosh
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-11       Impact factor: 2.566

5.  Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.

Authors:  M P Sparrow; S A Hande; S Friedman; W C Lim; S I Reddy; D Cao; S B Hanauer
Journal:  Aliment Pharmacol Ther       Date:  2005-09-01       Impact factor: 8.171

6.  Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism.

Authors:  D Q Shih; M Nguyen; L Zheng; P Ibanez; L Mei; L Y Kwan; K Bradford; C Ting; S R Targan; E A Vasiliauskas
Journal:  Aliment Pharmacol Ther       Date:  2012-07-11       Impact factor: 8.171

7.  Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis.

Authors:  Mark T Osterman; Rabi Kundu; Gary R Lichtenstein; James D Lewis
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

8.  Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.

Authors:  P W Lowry; C L Franklin; A L Weaver; C L Szumlanski; D C Mays; E V Loftus; W J Tremaine; J J Lipsky; R M Weinshilboum; W J Sandborn
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

9.  Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.

Authors:  A Ansari; C Hassan; J Duley; A Marinaki; E-M Shobowale-Bakre; P Seed; J Meenan; A Yim; J Sanderson
Journal:  Aliment Pharmacol Ther       Date:  2002-10       Impact factor: 8.171

10.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

Authors:  J F Rahier; S Ben-Horin; Y Chowers; C Conlon; P De Munter; G D'Haens; E Domènech; R Eliakim; A Eser; J Frater; M Gassull; M Giladi; A Kaser; M Lémann; T Moreels; A Moschen; R Pollok; W Reinisch; M Schunter; E F Stange; H Tilg; G Van Assche; N Viget; B Vucelic; A Walsh; G Weiss; Y Yazdanpanah; Y Zabana; S P L Travis; J F Colombel
Journal:  J Crohns Colitis       Date:  2009-04-26       Impact factor: 9.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.